We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tesla
TSLA
$1.3T
| $227M | 0.51% |
1,012,848
+27,090
| +3% | +$7.39M |
|
|
27
LyondellBasell Industries
LYB
$19.2B
| $219M | 0.5% |
2,533,980
+1,243,077
| +96% | +$130M |
|
28
Texas Instruments
TXN
$261B
| $216M | 0.49% |
1,426,416
-350,778
| -20% | -$59M |
|
29
Allstate
ALL
$67.5B
| $215M | 0.49% |
1,725,900
-1,023,444
| -37% | -$134M |
|
30
Citigroup
C
$226B
| $215M | 0.49% |
4,728,839
+2,419,202
| +105% | +$121M |
|
31
JPMorgan Chase
JPM
$950B
| $212M | 0.48% |
1,907,865
-417,318
| -18% | -$51.7M |
|
32
Micron Technology
MU
$991B
| $202M | 0.46% |
3,716,016
+1,731,289
| +87% | +$118M |
|
33
Abbott
ABT
$187B
| $200M | 0.45% |
1,854,226
-28,635
| -2% | -$3.25M |
|
34
ConocoPhillips
COP
$141B
| $199M | 0.45% |
2,216,554
+80,878
| +4% | +$8.33M |
|
35
Public Storage
PSA
$61.3B
| $197M | 0.44% |
632,696
-31,471
| -5% | -$10.9M |
|
36
Adobe
ADBE
$105B
| $195M | 0.44% |
542,845
+126,306
| +30% | +$51.4M |
|
37
Everest Group
EG
$14.4B
| $188M | 0.43% |
681,939
+4,379
| +0.6% | +$1.24M |
|
38
Verizon
VZ
$196B
| $178M | 0.4% |
3,515,492
+732,616
| +26% | +$37.1M |
|
39
Moderna
MRNA
$23.6B
| $177M | 0.4% |
1,284,567
-80,803
| -6% | -$11.5M |
|
40
Eli Lilly
LLY
$1.06T
| $174M | 0.39% |
538,336
-331,785
| -38% | -$99.6M |
|
41
Home Depot
HD
$355B
| $174M | 0.39% |
645,374
-294,171
| -31% | -$86.9M |
|
42
AT&T
T
$163B
| $173M | 0.39% |
8,286,499
+2,223,093
| +37% | +$44.3M |
|
43
Wells Fargo
WFC
$264B
| $171M | 0.39% |
4,437,545
+1,707,261
| +63% | +$74.9M |
|
44
American International
AIG
$41.3B
| $168M | 0.38% |
3,371,929
+2,148,227
| +176% | +$125M |
|
45
Visa
V
$677B
| $166M | 0.38% |
859,570
+148,930
| +21% | +$30.8M |
|
46
Cummins
CMI
$88.7B
| $166M | 0.37% |
874,198
-27,809
| -3% | -$5.56M |
|
47
Accenture
ACN
$108B
| $163M | 0.37% |
591,967
-244,440
| -29% | -$73.4M |
|
48
Colgate-Palmolive
CL
$74.4B
| $162M | 0.37% |
2,034,959
+223,446
| +12% | +$17.5M |
|
49
Chevron
CVX
$366B
| $161M | 0.36% |
1,110,806
-113,594
| -9% | -$18.8M |
|
|
50
Walmart Inc
WMT
$890B
| $158M | 0.36% |
3,922,992
-2,970,498
| -43% | -$137M |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.